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Abstract
Members of the carcinoembryonic antigen cell adhesion molecules (CEACAMs) family are the prototype of tumour markers.
Classically they are used as serum markers, however, CEACAMs could serve as targets for molecular imaging as well. In
order to test the anti CEACAM monoclonal antibody T84.1 for imaging purposes, CEACAM expression was analysed using
this antibody. Twelve human cancer cell lines from different entities were screened for their CEACAM expression using
qPCR, Western Blot and FACS analysis. In addition, CEACAM expression was analyzed in primary tumour xenografts of these
cells. Nine of 12 tumour cell lines expressed CEACAM mRNA and protein when grown in vitro. Pancreatic and colon cancer
cell lines showed the highest expression levels with good correlation of mRNA and protein level. However, when grown in
vivo, the CEACAM expression was generally downregulated except for the melanoma cell lines. As the CEACAM expression
showed pronounced expression in FemX-1 primary tumours, this model system was used for further experiments. As the
accessibility of the antibody after i.v. application is critical for its use in molecular imaging, the binding of the T84.1
monoclonal antibody was assessed after i.v. injection into SCID mice harbouring a FemX-1 primary tumour. When applied
i.v., the CEACAM specific T84.1 antibody bound to tumour cells in the vicinity of blood vessels. This binding pattern was
particularly pronounced in the periphery of the tumour xenograft, however, some antibody binding was also observed in
the central areas of the tumour around blood vessels. Still, a general penetration of the tumour by i.v. application of the anti
CEACAM antibody could not be achieved despite homogenous CEACAM expression of all melanoma cells when analysed in
tissue sections. This lack of penetration is probably due to the increased interstitial fluid pressure in tumours caused by the
absence of functional lymphatic vessels.
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Introduction
Members of the carcinoembryonic antigen (CEACAM) family
are transmembrane glycoproteins belonging to the immunoglob-
ulin superfamily, which are involved in a variety of biological
processes [1,2]. These include regulation of cell growth,
differentiation, immune response, cellular recognition and cell
adhesion [3,4,5,6]. In addition to their normal function,
expression of several members of the CEACAM family was found
to be upregulated in colorectal and lung cancer as well as in
melanoma [7,8,9]. Due to their up-regulation in these entities,
members of the CEACAM family have served as valuable clinical
markers both in tissue sections and patients’ sera [10,11]. In
particular, the classical serum marker CEACAM5 (CEA) is highly
expressed in cancers including colorectal, gastric, pancreatic, and
small cell lung cancer [12,13,14]. Because of their high expression
level in colon cancer, serum CEA levels are routinely used to
monitor the recurrence of colonic adenocarcinoma after surgery
and some of the antibodies have been used in patient studies
[15,16,17].
However, marker analysis of serum samples does not disclose
the site of CEA production and therefore the site of the (primary)
tumour remains unresolved by serum analysis. To localise
tumours, endoscopic as well as non-invasive imaging techniques
like MRI are used, which, however, lack information about the
specific proteins secreted by the tumour including CEA. To obtain
information about the specific molecular composition of tumours,
MRI techniques have to be combined with antibody based
technologies resulting in molecular imaging techniques [18].
To discover the capabilities and limitations of molecular
imaging we developed murine xenograft models for in vivo
detection of CEACAMs. CEACAMs were chosen for targeting
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as they are often highly expressed in a variety of malignancies (see
above). In order to broaden the specificity of our molecular probe,
we used the T84.1 monoclonal antibody which is capable of
recognising several members of the CEACAM family including
CEACAM 1, 5 and 6 [19].
This contribution describes the expression of T84.1 immuno-
reactivity in 12 different human cancer cell lines for CEACAM
expression in vitro and when grown in immunodeficient mice in vivo
as primary tumour in order to establish a xenograft model for
CEACAM detection. With one of these models we additionally
investigated the accessibility of CEACAMs to antibodies in the
primary tumour after i. v. application of the anti pan-CEACAM
antibody T84.1.
Materials and Methods
Cell lines
The human prostate cancer cell lines LNCAP [20] and PC3
[21] (both established from metastatic adenocarcinomas) were
obtained from the German Collection of Microorganisms and Cell
Culture (DSMZ, Germany). The human breast cancer cell lines
T47D [22] and MCF7 [22] (both established from pleural
effusions) were obtained from European Cell Culture Collection
(Porton Down, Wiltshire, UK). The human melanoma cell lines
MEWO [23] and FemX-1 [24] (both established from metastatic
melanoma lymph nodes) were kindly provided by the Klinik fu¨r
Dermatologie, Universita¨tsklinikum Hamburg-Eppendorf, Ger-
many. The human colon cancer cell line HT29 [25] (established
from a primary carcinoma of the colon) was obtained from Cell
Lines Service (Germany). The human colon cancer cell lines
Caco2 and SW480 [22] (both established from primary adeno-
carcinomas of the colon) were obtained from European Cell
Culture Collection (Porton Down, Wiltshire, UK). The human
small cell lung cancer cell line OH-1 [26] (established from pleural
effusion) was kindly provided by Prof. Uwe Zangemeister-Wittke,
University of Berne, Department of Pharmacology. The human
pancreatic cancer cell line 5061 [27] (established from a advanced
pancreatic adenocarcinoma) was kindly provided by the Klinik
und Poliklinik fu¨r Allgemein-, Viszeral- und Thoraxchirurgie,
Universita¨tsklinikum Hamburg-Eppendorf, Germany. The human
prancreatic cell line 5072 (established from a advanced pancreatic
adenocarcinoma from a 71-year-old Caucasian woman) was
kindly provided by the Klinik und Poliklinik fu¨r Allgemein-,
Viszeral- und Thoraxchirurgie, Universita¨tsklinikum Hamburg-
Eppendorf, Germany. Histopathological examination of the
surgical specimen confirmed a low-differentiated adenocarcinoma
of the pancreas, which was staged pT3, pN2, G3, M0, R0. Written
informed consent of the patient for the removal of tissue samples
for investigational purposes was obtained prior to surgery. The
study was approved by the ethical committee of the Medical
Council of Hamburg (A¨rztekammer), Germany.
The cell lines LNCAP, PC3, T47D, MCF7, MEWO, FemX-1,
HT29, Caco2, SW480, OH-1 were cultured in vitro under
standard cell culture conditions (37uC, 100% relative humidity,
5% CO2) in RPMI medium (Gibco/Life Technologies, Paisley,
Scotland) supplemented with 10% heat inactivated fetal bovine
serum (FBS, Gibco), 2 mM L-glutamine (Gibco), 100 U/ml
penicillin and 100 mg/ml streptomycin (Gibco). The cell lines
5061 and 5072 were cultured in complete (TUM) RPMI 1640
medium with Glutamax (Invitrogen, NY, USA) supplemented
with 10% of fetal calf serum (FCS), 200 IU/ml of penicillin-
streptomycin, 0.1 mg/ml gentamycin (Biochrom AG, Berlin,
Germany), 50 nmol/ml of human transferrin (Sigma-Aldrich,
Steinheim, Germany), 0.01 mg/ml of bovine insulin (Sigma-
Aldrich, Steinheim, Germany), 0.01 mg/ml of recombinant
human epidermal growth factor (Pepro Tech, London, UK),
and 0.01 mg/ml of human basic fibroblast growth factor (Pepro
Tech, London, UK). Before reaching confluence, cells were
routinely harvested for passaging using 0.05% trypsin-0.02%
EDTA (Gibco).
Real-time PCR
To quantify CEACAM mRNA amount in relation to GAPDH
mRNA amount of the human tumour cell lines, real-time PCR
was carried out. In brief, total RNA from tumour cells was isolated
using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. The RNA was eluted in 50 ml
RNase free water. The RNA-concentration was measured and the
quality was checked on a NanoDropH ND-1000 Spectrophotom-
eter (Peqlab, Erlangen, Germany). The cDNA synthesis was
performed in a Biometra thermal cycler (Biometra, Go¨ttingen,
Germany) in a total volume of 20 ml for each sample and followed
the manufacturer’s instruction for the First Strand Transcriptor
cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany).
Two parallel cDNA approaches were used for reverse transcrip-
tion separately, with anchored-oligo(dT)18 and random hexamer
primer. Two mg of total RNA were used for each cDNA approach
and were pooled afterwards. Real-time polymerase chain reaction
was performed in a 96 well format with the LightCyclerH 480
System (Roche Diagnostics GmbH, Mannheim, Germany). For
the real-time PCR, the LightCycler Fast Start DNA MasterPLUS
SYBRGreen I Kit (Roche Diagnostics GmbH, Mannheim,
Germany) was used. Two ml of cDNA was used as a template
for the PCR reaction and incubated in a total reaction volume of
10 ml, containing 16SYBR Green I Master mix including Taq
DNA polymerase, Taq PCR buffer, a dNTP mixture and
1 mmol/l MgCl2, 10 pmol specific CEACAM or GAPDH
primers. Forward CEACAM primer (TGT GAA TGA AGA
AGC AAC), reverse CEACAM primer (CAG CCT GGG ACT
GAC CGG), forward GAPDH primer (AAA TTG AGC CCG
CAG CCT CCC), and reverse GAPDH primer (CCA GGC GCC
CAA TAC GAC CAA AT) were synthesized by MWG-
BIOTECH AG (Ebersberg, Germany). The PCR conditions were
initially 5 min 95uC, followed by 40 cycles of 10 s 95uC, 10 s 62uC
(CEACAM) or 72uC (GAPDH) and 20 s 72uC, respectively. The
primer pair detects in parallel CEACAM 1, 5 and 6.
Protein extraction and Western blotting
Total protein extracts from cell lines were obtained by lysing the
cells in cold radioimmunoprecipitation assay (RIPA) buffer (50 mM
Tris, 2 mM EDTA, 1% NP-40, 0.1% SDS, and 150 mM NaCl) in
the presence of protein inhibitor cocktail set I (Calbiochem, La Jolla,
USA). After centrifugation to remove cell debris, protein concen-
trations of the supernatants were measured using the BCA method
[28]. 40 mg protein per lane were resuspended in loading buffer
(0.5 M Tris-HCl, pH 6.8, glycerol, 10% SDS, 0.5% bromphenol
blue, mercaptoethanol) and then subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (8% gels). Proteins were
subsequently blotted onto a nitrocellulose membrane (HybondH-
ECLH, Amersham Biosciences, Freiburg, Germany) following
conventional protocols. Finally, blots were blocked in 4% bovine
serum albumin/Tris-buffered saline–0.1% Tween 20 (TBS-T) for
30 min at room temperature. Membranes were incubated with
primary antibody T84.1 (1 mg/ml) and anti-beta-Actin (0.5 mg/ml,
Abcam, Cambridge, UK) over night at 4uC, washed with TBS-T
and incubated with a 1:200 diluted polyclonal goat-anti-mouse
antibody (DakoCytomation, Carpinteria, USA) conjugated with
horseradish peroxidase for 60 min at room temperature. The
CEACAM as Target for Molecular Imaging
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bound immune complexes were visualised using ECL Western
Blotting Substrate (Pierce, Rockford, USA) and the ChemiDoc
XRS System (Bio-Rad, Munic, Germany).
Flow Cytometry
Cultured cells were detached with Cell Dissociation Buffer
(GIBCOTM, Carlsbad, US) and incubated on ice for 30 min with
T84.1 primary antibody at a concentration of 1 mg/ml. The
corresponding murine isotype control was IgG1 (DakoCytoma-
tion, Carpinteria, USA). The cells were washed and the primary
antibody was detected with allophycocyanin-conjugated goat-anti-
mouse antibody (Becton Dickinson Biosciences, Heidelberg,
Germany). Flow cytometry was performed using a FACS
CALIBUR flow cytometer (Becton Dickinson, Heidelberg,
Germany). Data were analyzed using Win MDI 2.9 software.
Immunochemistry
For immunocytochemistry, cells cultured in eight-well chamber
slides (Becton Dickinson, Heidelberg, Germany) were washed with
PBS, fixed in ice-cold acetone for 2 min, air dried, and blocked
with 10% rabbit sera in blocking reagent (TBS). Slides then were
incubated with T84.1 or IgG1 control antibody at a dilution of
0,6 mg/ml over night (4uC) followed by a biotinylated rabbit anti
mouse antibody (DakoCytomation) at a dilution of 1:200 for
30 min. After careful washes in TBS, an incubation with an
avidin-alkaline phosphatase complex (ABC kit, Vectastain, Vector,
Burlingame, CA) for 30 min followed and thereafter, additional
washes in TBS were performed. Alkaline phosphatase activity was
visualised using Naphthol-AS-bisphosphate as a substrate and
New Fuchsin was used for simultaneous coupling. Slides were
counterstained with Mayer’s hemalum diluted 1:1 in distilled
water for ten seconds, blued under running tap water and
mounted with AquatexH (Merck KGaA, Darmstadt, Germany).
The intensity (plus signs) and extent (percentage) of the positive
areas of five histological sections were determined by visual
inspection of three independent observers. The plus sign indicates
the intensity of the staining. It ranges from ‘‘+++’’ to ‘‘2’’. The
percentage indicates how many cells are labelled.
Immunohistochemistry of tumour cell lines
xenotransplanted in SCID mice
Sections of all primary tumors were drawn from our in house
tumor bank. They had all been fixed with 4% formalin and
embedded in paraffin wax according to standard procedures. For
immunohistochemistry, 5 mm thick sections were cut, dewaxed
and microwaved in 10 mM citrate buffer (pH 6.0) at 500 W five
times for 2 min and then cooled for 20 min. After washing, non-
specific binding was blocked by incubating the sections in 10%
normal rabbit serum (DAKO, Hamburg, Germany) for 30 min at
room temperature. The following steps were as described above.
Ethics Statement
The methodology for carrying out the experiment was
consistent with the UKCCCR guidlines for the welfare of animals
in cancer research [29]. The experiment was supervised by the
institutional animal welfare officer and approved by the local
licensing authority (Beho¨rde fu¨r Soziales, Familie, Gesundheit und
Verbraucherschutz; Amt fu¨r Gesundheit und Verbraucherschutz,
Hamburg, Germany, project no. 92/09).
In vivo experiments
To investigate in vivo CEACAM binding sites, specific pathogen-
free BALB/c SCID (scid/scid) mice were used. The mice were 8–
16 weeks old and weighed 20–30 g at the beginning of our
experiments. They were housed in filter top cages and provided
with sterile water and food ad libitum. For injection, FemX-1
melanoma cells were harvested by trypsination and viable cells
(56106) were suspended in 1 ml of cell culture medium. An aliquot
of 200 ml of this suspension was injected subcutaneously between
the scapulae of each SCID mouse. Twelve mice bearing
melanomas were included in the experiment when the tumour
had reached maximal growth or started to ulcerate.
Iodination of antibodies was done by Iodobeads (Pierce,
Rockford, USA). Specifically, 5 ml sodium [125I]Iodine
(3.7 MBq/ml, Amersham, UK) was added to 1 mg T84.1 or
control IgG1 in 1 ml PBS in the presence of one Iodobead and the
reaction was left for 15 min. Free [125I]Iodine was removed by
exclusion chromatography through a PD-10 column (GE
Healthcare, Buckinghamshire, UK). The protein concentration
was determined by the BCA method and the specific activity of the
[125I]-T84.1 and [125I]-IgG1 per mg protein was measured by
gamma counting (Perkin Elmer, Waltham, USA).
Ten mg of [125I]-labelled antibodies were injected via the tail
vein into FemX-1 melanoma bearing mice. Six mice received
[125I]-IgG1 and six mice [125I]-T84.1 antibody. After 0.5, 2.5, 6,
17.5, and 22.5 hours blood samples were taken by tail vein to
measure antibody blood half life. Afterwards mice were sacrificed,
intracardially perfused with NaCl and tumour and organs were
removed and weighted. Radioactivity of organs, tumours and
blood were determined in the gamma counter. Statistical analyses
(Two-way ANOVA) were performed using GraphPad Prism 5
software (GraphPad software, USA).
Evans Blue was injected i.v. at a dose of 25 ml (50 mg/ml PBS)
per FemX-1 s.c. bearing mouse 4 hours before scarification.
Anaesthetised mice were intracardially perfused with 1% BSA in
NaCl to remove free dye and afterwards fixed with 4% PFA.
Tumours were removed and embedded in 5% agarose gel, cut in
200 mm thick slices with a vibratome (VT1000E, Zeiss, Wetzlar,
Germany) and scanned with 2400 dpi on a scanner (Epson, Long
Beach, USA).
Results
CEACAM expression in vitro
The CEACAM expression levels of twelve human cancer cell
lines derived from different tumour entities are summarized in
figure 1 and table 1.
The highest expression of CEACAM mRNA was detected in
the pancreatic tumour cell lines 5061 and 5072, the colon cancer
cell lines HT29 and Caco2, and the prostate cancer cell line
LNCAP. Low levels could be found in the breast cancer cell lines
T47D and MCF7 and in the melanoma cell line FemX-1. Almost
no CEACAM expression could be detected in the lung cancer cell
line OH-1, the melanoma cell line MEWO, and the colon cancer
line SW480.
Presence of the CEACAM proteins was analyzed by Western
Blot of cell lysats (figure 2, table 1). All cell lines showed distinct
protein bands except for the cell line T47D, which showed only a
very faint band. Several bands were detected in the blots,
presumably because of the different glycosylation isoforms that
exists of the CEACAM proteins. No obvious correlation between
mRNA and protein levels was observed.
The amount of membrane bound CEACAM proteins were
furthermore determined by FACS analysis using mAb T84.1
(figure 3). As summarized in table 1, almost all cell lines showed
the same staining pattern, as seen in the immunocytochemistry.
CEACAM as Target for Molecular Imaging
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To visualize the CEACAM expression pattern under cell culture
conditions we stained the cells, grown on chamber slides, with the
panCEACAM T84.1. As shown in figure 4, the pancreatic (5061,
5072), colon (Caco2, HT29, SW480), and melanoma (FemX-1,
MEWO) cancer cell lines clearly bound mAb T84.1. Lower or no
binding could be detected by prostate (LNCAP, PC3) and breast
(MCF7, T47D) cancer cell lines.
CEACAM expression in vivo
Only FemX-1 and LNCAP primary xenograft tumours showed
strong mAb T84.1 binding by more than 50% of all cells (figure 4
and table 1), while all other primary tumours did not show
substantial T84.1 binding.
CEACAM binding detection in vivo
To analyse whether the CEACAM binding sites detected in
tissue sections were also accessible in vivo, [125I]-labelled T84.1
mAb and non-specific [125I]-labelled control IgG were injected
into the tail vein of FemX-1 melanoma bearing mice. A significant
two-fold higher enrichment of the [125I]-T84.1 mAb in the FemX-
1 melanoma was detected compared to the [125I]-IgG1 control
(figure 5) (Two-way ANOVA, P,0.001). There was no significant
difference concerning blood half life or tissue distribution between
specific [125I]-T84.1 mAB and control [125I]-IgG (figure 6).
In a parallel experiment the distribution of the injected mAbs
24 hours after application were analysed in histological sections
regarding tissue distribution of the antibody (figure 7). No
detectable levels of antibody could be found in control animals
injected with control IgG1 mAb. In contrast, T84.1 binding could
be detected at the margin of the tumour and in the central area of
the FemX-1 tumour around blood vessels.
To study the mechanism of T84.1 penetration of the tumour
tissue we investigated the tumour vessel permeability with an
alternative technique. We injected the albumin-binding dye Evans
Blue i.v. in FemX-1 melanoma bearing mice and investigated the
dye distribution in vibratome sections of the tumour. Evans Blue-
Albumin complex was present only around blood vessels, at the
margin of the tumour, and in the transition zone between vital
tumour tissue and central necrosis and thus was similar to the
T84.1 binding (figure 8).
Discussion
Identifying malignant tumours is one of the most important aims
of molecular imaging. In order to bring molecular imaging
techniques into clinical application, the technical approach has to
be validated in suitable animal models first [30]. We therefore
systematically investigated the CEACAM expression of twelve
human cancer cell lines and their primary tumour xenografts in
immunodeficient mice for their suitability to detect the tumour using
an anti CEACAM antibody as a pre-requisite for imaging studies.
As human cancer cell lines often serve as the first choice for
detecting human specific antigens, we analyzed CEACAM mRNA
Figure 1. CEACAMmRNA expression of human malignant cells.
The mRNA of the malignant cell lines 5061, 5072 (pancreas), PC3, LNCAP
(prostate), FemX-1, MEWO (melanoma), MCF7, T47D (breast), HT29
(colon) and OH-1 (small cell lung cancer) were relatively quantified by
real time PCR, using GAPDH for normalization. Cell lines 5061, 5072,
LNCAP and HT29 showed high expression levels of CEACAM mRNA.
doi:10.1371/journal.pone.0028030.g001
Table 1. Summary of in vitro and in vivo CEACAM expression of all cell lines by different methods.
cell culture xenografted tumor
QPCR WB FACS positive immunocytochemistry immunohistochemistry
5061 +++ + 99% +++ (95%) ++/+++ (45%)
5072 ++ + 77% +++ (90%) 2 (0%)
LNCAP ++ + 93% ++ (100%) ++/+++ (60%)
PC3 + + 23% ++ (10%) (+) (20%)
T47D + (+) 5% + (1%) +/++ (20%)
MCF7 + + 23% +++ (5%) +/++ (20%)
MEWO (+) + 74% +++ (85%) ++ (60%)
FemX-1 + + 95% +++ (100%) ++/+++ (90%)
HT29 ++ + 86% +++ (90%) ++ (45%)
Caco2 + + 16% +++ (90%) ++ (20%)
SW480 2 + 31% + (5%) (+) (30%)
OH-1 (+) + 80% ++ (80%) (+) (100%)
Note that the highest CEACAM expression in vitro and in vivo showed the melanoma cell line FemX-1. The intensity (plus signs) and extent (percent) of the positive areas
of 5 histological sections were determined by visual inspection of 3 independent observers.
doi:10.1371/journal.pone.0028030.t001
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expression in a panel of human malignant cell lines. This was
followed by the detection of their CEACAM protein expression in
Western Blots. We found that pancreatic and colon (except of
SW480) cancer cell lines have the highest expression levels of
CEACAM with good correlation between mRNA amount and
protein level in Western Blots. Similarly high protein levels were
detected in melanoma cells, but their mRNA level was generally
lower than that observed in the pancreatic and colon cancer cell lines.
This discrepancy between mRNA and protein expression levels has
already been observed e.g. in Saccharomyces cerevisae for the PUP2, and
by mammals for circadian Period2 gene [31,32]. RNA stability and/
or translational efficiency between the cancer cell lines and different
CEACAM family members could be a reason for the finding, that
low mRNA level were associated with high protein levels.
A further discrepancy in CEACAM expression was observed
between in vitro and in vivo CEACAM expression (figure 4). Except
Figure 2. Western blot analysis of the CEACAM protein expression pattern. CEACAM family members as detected by pan CEACAM specific
antibody T84.1 were present in all cancer cell lines except T47D. Beta-actin was used as a loading control.
doi:10.1371/journal.pone.0028030.g002
Figure 3. CEACAM cell surface presence of tumour cells. CEACAM could positively be detected by FACS-analysis with mAb T84.1 by all cancer
cell lines, except of T47D, MCF7 and PC3. Isotype controls are shown as dotted lines.
doi:10.1371/journal.pone.0028030.g003
CEACAM as Target for Molecular Imaging
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melanomas, all malignant cell lines showed a downregulation of
CEACAM expression in vivo as compared to in vitro. CEACAM
family members are mainly expressed by epithelial and endothelial
cells at the free surface of their apical pole [33,34]. In contrast to
the three dimensional growth in vivo where tumour cells form a 3D
conglomerate of cells with only a few free surfaces, almost all
cultured cells have exposed free surfaces and therefore almost all
cells display an apical cell pole enabling them to express
CEACAM at this interface to the cell culture medium. This
different growth behaviour results in a down regulation of
CEACAM in the primary tumours compared to the cell culture
growth.
The observation that the melanoma cell line showed the highest
CEACAM expression level might not be so unexpected, as periodic
acid-Schiff (PAS) reaction positive loops and networks indicating
micro vascular channels within melanoma have been described
[35]. As these microvascular channels are lined by the melanoma
cells themselves and are not covered by endothelial cells, this apical
surface might provide additional space for CEACAM expression. A
further reason for the difference in expression can be found in
tumour - stroma interactions. Cancer cells in a tumour xenograft
are exposed to mouse extracellular matrix and mouse cells like
blood vessel endothelia, lymphocytes and macrophages and also to
mouse hormones. All these tumor-stroma interactions can poten-
tially alter the expression of genes in the human tumour cell in
xenografts [36]. The few regions of higher CEACAM expression in
vivo in the xenograft of cell line T47D could be explained by the fact,
that hypoxia could upregulate CEACAM expression via HIF1a
signaling. A HIFa response element is located in the promoter
region of CEACAM [37].
Another factor to be investigated is the accessibility of the
monoclonal antibody to the CEACAM binding sites after i.v.
Figure 4. CEACAM protein expression pattern in vivo and in vitro. Cell lines LNCAP and FemX-1 showed in vitro and in vivo strong binding of
mAb T84.1 by all cells. In contrast, cell lines 5061, MEWO, OH-1 (insert with higher magnification) HT29, Caco2, and particularly 5072 showed strong
mAb T84.1 in vitro binding, but little or no binding in vivo. (red = T84.1 binding).
doi:10.1371/journal.pone.0028030.g004
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application of the T84.1 antibody. Using labelled lectins as a
probe, we have previously shown that vast differences in lectin
binding site accessibility existed between the binding of the lectins
to tissue sections and to the same tissue after i.v. injection of the
same lectins [38]. We therefore investigated the presence of
CEACAM binding sites in vivo using the CEACAM specific T84.1
mAB on FEMX-1 cells after its i.v. application. FEMX-1 cells
were chosen as they readily grow in SCID mice and additionally
show robust CEACAM expression in vitro and in vivo (figure 4). We
could indeed show that the i.v. applied antibody reaches the target,
but to a moderate extent only as its presence was limited to the
direct vicinity of blood vessels (figure 5 and 7). Furthermore,
melanoma is a particularly well suited malignancy to be
investigated as CEACAM expression is positively correlated with
metastasis formation [9]. Therefore more malignant cells express
CEACAM-1 in melanoma, while in other tumour entities such as
breast or prostate cancer CEACAM-1 expression is down-
regulated during malignant progression [39,40].
A known phenomenon of tumour xenografts is the uneven
distribution of blood vessels within different areas of the tumour
[41]. In our FemX-1 melanoma model the vascular density was
more intense in the periphery than in the centre of the tumour
xenograft (figure 8). The access of the T84.1 antibodies was limited
to areas around blood vessels, resembling Kroghs’ cylinder which
shows the limits of oxygen diffusion in tissues [42]. Even the Evans
Blue-Albumin complex with a lower mass weight of 67 kDa could
only be found in the same area, as the injected T84.1 antibody
(figure 8). All transport processes beyond this cylinder are not
based on diffusion but on convection. Convection, however, is
severely altered in tumours because of the absence of functional
lymphatic vessels within the tumour. This leads to an accumula-
tion of interstitial fluid within tumours resulting in a high
interstitial fluid pressure of tumours which could be the
pathophysiological mechanism behind this finding of a limited
access of the antibody to the melanoma cells, despite the presence
of microvascular channels in melanomas [43,44].
The process of diffusion allows only the penetration of small
molecules into the tumour, the size of the whole antibody molecule
is obviously far too big to target cells behind the endothelial barrier
as the target molecule CEACAM is clearly expressed in the
tumour as shown in tissue sections. Therefore, the access of i.v.
administrated anti CEACAM antibodies is limited to tumour cells
surrounding blood vessels despite the fact, that many more tumour
cells express CEACAM if studied in tissue sections. This lack of
penetration might also explain why studies on the usage of anti
CEA antibodies have not found acceptance in routine clinical
practice [16,17]. In order to target a wider range of CEACAM
positive tumour cells, smaller target-specific molecules like
DARPINs or nanobodies against CEACAM will be tested to see
Figure 5. CEACAM in vivo binding. [125I]-Labelled T84.1 and
nonspecific [125I]-labelled IgG1 antibody were used for CEACAM in vivo
binding in FemX-1 melanoma bearing SCID mice. There is a significant
difference between specific and control antibody by FemX-1 melano-
ma, but not in other organs including blood (Two-way ANOVA,
P,0.001, n = 6).
doi:10.1371/journal.pone.0028030.g005
Figure 6. Blood half life of mAbs T84.1 and IgG1. The blood half
life of [125I]-labelled T84.1 and nonspecific [125I]-labelled IgG1 antibodies
were determined in FemX-1 tumour bearing SCID mice. The blood half
life of specific and control antibody were identical (T84.1 = 10.3 h
(n = 4), IgG1= 10.4 h (n = 4)).
doi:10.1371/journal.pone.0028030.g006
Figure 7. CEACAM in vivo detection of FemX-1 tumour. A: T84.1-
antibody binds to FemX-1 tumour cells in vivo after i.v. injection of
T84.1- (50 mg) in tumour bearing mice, as visualized in cryostat sections
with subsequent immunostaining against T84.1-antibody (red= T84.1
positive cells) in sections of the primary tumour. B: Controls using IgG1
ab (40 mg) proved the high specificity of T84.1 binding to tumour cells
in vivo. The specific antibody T84.1 binding was detected at the entire
margins of the tumour, which is well supplied with blood vessels. In
contrast, T84.1 binding was only observed around blood vessels in the
central area of the tumour.
doi:10.1371/journal.pone.0028030.g007
Figure 8. Evans Blue-Albumin complex distribution in vibra-
tome sections of FemX-1 melanoma. Evans Blue-Albumin complex
positive areas (blue) are recognizable at blood vessels in vital tumour
tissue (a), at the tumour margin (c) and the transition (d) between vital
tumour tissue and necrosis (b).
doi:10.1371/journal.pone.0028030.g008
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if they could reach the in vivo CEACAM binding sites to a greater
extent. However, we could show that the target CEACAM could
be studied with our melanoma FEMX-1 model and used for
molecular imaging.
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